Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia.

doi:10.1200/JCO.2013.52.3480

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 May 2014

Pastore Friederike, Dufour Annika, Benthaus Tobias, Metzeler Klaus H, Maharry Kati S, Schneider Stephanie, Ksienzyk Bianka, Mellert Gudrun, Zellmeier Evelyn, Kakadia Purvi M, Unterhalt Michael, Feuring-Buske Michaela, Buske Christian, Braess Jan, Sauerland Maria Cristina, Heinecke Achim, Krug Utz, Berdel Wolfgang E, Buechner Thomas, Woermann Bernhard, Hiddemann Wolfgang, Bohlander Stefan K, Marcucci Guido, Spiekermann Karsten, Bloomfield Clara D, Hoster Eva

Abstract excerpt

PURPOSE: Cytogenetically normal (CN) acute myeloid leukemia (AML) is the largest and most heterogeneous cytogenetic AML subgroup. For the practicing clinician, it is difficult to summarize the prognostic information of the growing number of clinical and molecular markers. Our purpose was to develop a widely applicable prognostic model by combining well-established pretreatment patient and disease characteristics....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CCAAT-Enhancer-Binding Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytogenetic Analysis

Share to Decision Support Techniques

Share to Disease-Free Survival

Share to fms-Like Tyrosine Kinase 3

Share to Germany

Share to Nucleophosmin

Share to Proportional Hazards Models

Source

Open in PubMed Open full text

Identifiers

PMID: 24711548
DOI: 10.1200/JCO.2013.52.3480
PMCID: PMC4876345

Genes

FLT3
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia.PMID 24711548Read ↗

Integrative prognostic risk score in acute myeloid leukemia with normal karyotypeSemantic proximity Read ↗

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.Semantic proximity Read ↗

Refinement of Risk-Stratification of Cytogenetically Normal Acute Myeloid Leukemia Adult Patients by MN1 Expression.Semantic proximity Read ↗

Molecular prognostic factors in cytogenetically normal acute myeloid leukemia.Semantic proximity Read ↗

Management of patients with cytogenetically normal acute myeloid leukemia who have neither favorable nor unfavorable markers.Semantic proximity Read ↗

Prognostic factors for acute myeloid leukaemia in adults - biological significance and clinical useSemantic proximity Read ↗

Molecular prognostic markers for adult acute myeloid leukemia with normal cytogeneticsSemantic proximity Read ↗

A novel 5-gene prognostic signature to improve risk stratification of cytogenetically normal acute myeloid leukemia.Semantic proximity Read ↗

Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia.Semantic proximity Read ↗

A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia.Semantic proximity Read ↗

Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study.Semantic proximity Read ↗

A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.